$CPIX
CUMBERLAND PHARMACEUTICALS INC

2023 Q4 Form 10-Q Financial Statement

#000162828023038418 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $9.353M $10.09M
YoY Change 2.51% -11.63%
Cost Of Revenue $1.530M $1.766M
YoY Change -65.62% -20.63%
Gross Profit $7.823M $8.320M
YoY Change 67.4% -9.45%
Gross Profit Margin 83.64% 82.49%
Selling, General & Admin $8.198M $7.087M
YoY Change 19.04% 12.91%
% of Gross Profit 104.8% 85.18%
Research & Development $1.265M $1.925M
YoY Change -10.04% 12.28%
% of Gross Profit 16.17% 23.13%
Depreciation & Amortization $1.233M $1.246M
YoY Change 141.12% -19.32%
% of Gross Profit 15.76% 14.98%
Operating Expenses $14.00M $9.012M
YoY Change 60.01% 12.78%
Operating Profit -$6.179M -$1.867M
YoY Change 171.28% 546.81%
Interest Expense -$97.79K $110.1K
YoY Change -26.89% -26.29%
% of Operating Profit
Other Income/Expense, Net $0.00 $821.8K
YoY Change
Pretax Income -$6.277M -$1.056M
YoY Change 160.29% 153.71%
Income Tax $24.96K $6.938K
% Of Pretax Income
Net Earnings -$6.294M -$1.049M
YoY Change 157.89% 156.78%
Net Earnings / Revenue -67.3% -10.4%
Basic Earnings Per Share -$0.44 -$0.07
Diluted Earnings Per Share -$0.44 -$0.07
COMMON SHARES
Basic Shares Outstanding 14.26M shares 14.37M shares
Diluted Shares Outstanding 14.28M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.32M $18.51M
YoY Change -7.27% -5.29%
Cash & Equivalents $18.32M $18.51M
Short-Term Investments
Other Short-Term Assets $3.025M $1.971M
YoY Change -1.94% -47.28%
Inventory $4.609M $8.671M
Prepaid Expenses
Receivables $9.758M $12.62M
Other Receivables $0.00 $0.00
Total Short-Term Assets $35.71M $41.77M
YoY Change -22.14% -15.03%
LONG-TERM ASSETS
Property, Plant & Equipment $7.042M $377.4K
YoY Change 2379.34% -23.1%
Goodwill $914.0K $914.0K
YoY Change 0.0% -52.71%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.50M $2.556M
YoY Change 514.82% 5.3%
Total Long-Term Assets $46.06M $45.98M
YoY Change -2.11% 10.49%
TOTAL ASSETS
Total Short-Term Assets $35.71M $41.77M
Total Long-Term Assets $46.06M $45.98M
Total Assets $81.78M $87.75M
YoY Change -12.0% -3.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.04M $10.82M
YoY Change 29.75% -6.02%
Accrued Expenses $348.1K $334.3K
YoY Change -98.02% 45.59%
Deferred Revenue $220.4K
YoY Change -64.14%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $27.98M $27.33M
YoY Change -2.09% 7.99%
LONG-TERM LIABILITIES
Long-Term Debt $12.78M $12.92M
YoY Change -21.09% -26.99%
Other Long-Term Liabilities $11.75M $6.455M
YoY Change 54.91% -30.43%
Total Long-Term Liabilities $24.53M $6.455M
YoY Change 223.45% -76.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.98M $27.33M
Total Long-Term Liabilities $24.53M $6.455M
Total Liabilities $52.17M $52.10M
YoY Change -8.39% -0.36%
SHAREHOLDERS EQUITY
Retained Earnings -$17.49M -$11.19M
YoY Change 56.02% 27.66%
Common Stock $47.19M
YoY Change -0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.60M $35.99M
YoY Change
Total Liabilities & Shareholders Equity $81.78M $87.75M
YoY Change -12.0% -3.33%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$6.294M -$1.049M
YoY Change 157.89% 156.78%
Depreciation, Depletion And Amortization $1.233M $1.246M
YoY Change 141.12% -19.32%
Cash From Operating Activities $1.040M $1.237M
YoY Change -71.41% -53.08%
INVESTING ACTIVITIES
Capital Expenditures $86.72K $95.07K
YoY Change -94.71% -143.5%
Acquisitions
YoY Change
Other Investing Activities $347.4K $0.00
YoY Change -65.26% -100.0%
Cash From Investing Activities $260.6K -$95.07K
YoY Change -140.67% -113.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.487M -882.6K
YoY Change -46.52% -55.67%
NET CHANGE
Cash From Operating Activities 1.040M 1.237M
Cash From Investing Activities 260.6K -95.07K
Cash From Financing Activities -1.487M -882.6K
Net Change In Cash -186.4K 258.9K
YoY Change -186.11% -80.46%
FREE CASH FLOW
Cash From Operating Activities $1.040M $1.237M
Capital Expenditures $86.72K $95.07K
Free Cash Flow $953.4K $1.141M
YoY Change -52.26% -60.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1971164 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3084978 usd
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14217926 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14217926 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
47185304 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
47474973 usd
CY2023Q3 us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P3Y
CY2023Q3 cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
475000 usd
CY2022Q3 cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
0 usd
CY2023Q3 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
346800 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
149340 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1056281 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-416326 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6938 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6900 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1063219 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-423226 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13921 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14587 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1049298 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-408639 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.07
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.03
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.21
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.07
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.21
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14277229 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14477478 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14277229 shares
us-gaap Share Based Compensation
ShareBasedCompensation
271146 usd
us-gaap Share Based Compensation
ShareBasedCompensation
320598 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1017712 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1051908 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
11713 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
7608 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
346800 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
611330 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-890361 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8184656 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-418355 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1338881 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
439320 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4355396 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1903021 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8778631 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-327329 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2472453 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5053700 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4815365 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232595 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255676 usd
cpix Proceeds From Settlement Of Patent Litigation
ProceedsFromSettlementOfPatentLitigation
0 usd
cpix Proceeds From Settlement Of Patent Litigation
ProceedsFromSettlementOfPatentLitigation
21757 usd
us-gaap Proceeds From Life Insurance Policies
ProceedsFromLifeInsurancePolicies
0 usd
us-gaap Proceeds From Life Insurance Policies
ProceedsFromLifeInsurancePolicies
877597 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
13500000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
133739 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
177362 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-366334 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13033684 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
23775000 usd
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
46700000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
27051875 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
44000000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2108933 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1117576 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
551563 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
863383 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5937371 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
719041 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1250005 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7499278 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19757970 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27040816 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18507965 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19541538 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
42601978 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
159901 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
566043 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-1402433 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40793403 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
40793403 usd
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1364666 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39204292 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
188449 usd
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
78793 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-423226 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38890722 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35974006 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
90156 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
187961 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
172286 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36048487 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
97877 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
171616 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
862154 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36836902 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36836902 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
83112 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
201237 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-1063219 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35655558 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns, (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liabilities associated with business combinations.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1049298 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-408639 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14277229 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14477478 shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14277229 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14477478 shares
us-gaap Net Income Loss
NetIncomeLoss
15086 usd
us-gaap Net Income Loss
NetIncomeLoss
-3129512 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14343560 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14618975 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
178040 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14521600 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14618975 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
440389 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
233750 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10085926 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
100000 usd
us-gaap Sublease Income
SubleaseIncome
400000 usd
us-gaap Sublease Income
SubleaseIncome
400000 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
500000 usd
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
8300000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7500000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12052652 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12899659 usd
CY2023Q3 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
191957 usd
CY2022Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
168923 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4727784 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4322166 usd
CY2023Q3 us-gaap Inventory Gross
InventoryGross
16972393 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
17390748 usd
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
8301845 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
7527167 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
8670548 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
9863581 usd
CY2021Q4 cpix Lessee Operating Lease Rent Increase
LesseeOperatingLeaseRentIncrease
0.025
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6711155 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5218403 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
334288 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172910 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5388900 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4586301 usd
CY2023Q3 cpix Lease Liability
LeaseLiability
5723188 usd
CY2022Q4 cpix Lease Liability
LeaseLiability
4759211 usd
CY2023Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
1700000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
212656 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
863320 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
836100 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
909911 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
934180 usd
CY2023Q3 cpix Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
5588192 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9344359 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3621171 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5723188 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
244305 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
239647 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
765455 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
861398 usd
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
155025 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
128395 usd
us-gaap Sublease Income
SubleaseIncome
400524 usd
us-gaap Sublease Income
SubleaseIncome
424632 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14731 shares
CY2017Q4 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
100000000 usd
CY2021Q4 cpix Stock Issued During Period Shelf Registration Proceeds From Sale Of Corporate Securities
StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleOfCorporateSecurities
19000000 usd
CY2022Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
16200000 usd
CY2023Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
44100000 usd
cpix Other Income Including Settlement And Life Insurance Proceeds
OtherIncomeIncludingSettlementAndLifeInsuranceProceeds
3700000 usd
CY2023Q1 us-gaap Other Income
OtherIncome
1800000 usd
CY2023Q2 us-gaap Other Income
OtherIncome
1000000 usd
CY2023Q3 cpix Gain Loss Related To Settlement
GainLossRelatedToSettlement
500000 usd
CY2023Q3 us-gaap Insured Event Gain Loss
InsuredEventGainLoss
300000 usd
CY2023Q3 cpix Collaborative Arrangement Rights And Obligations Remaining Sales Milestone Payments
CollaborativeArrangementRightsAndObligationsRemainingSalesMilestonePayments
2000000 usd

Files In Submission

Name View Source Status
0001628280-23-038418-index-headers.html Edgar Link pending
0001628280-23-038418-index.html Edgar Link pending
0001628280-23-038418.txt Edgar Link pending
0001628280-23-038418-xbrl.zip Edgar Link pending
a2023q3-exhibit311.htm Edgar Link pending
a2023q3-exhibit312.htm Edgar Link pending
a2023q3-exhibit321.htm Edgar Link pending
cpix-20230930.htm Edgar Link pending
cpix-20230930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
cpix-20230930_cal.xml Edgar Link unprocessable
cpix-20230930_def.xml Edgar Link unprocessable
cpix-20230930_lab.xml Edgar Link unprocessable
cpix-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cpix-20230930_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending